Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > LATEST
LATEST
-
REGULATORY MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
-
BUSINESS Fuso Says Toray Jacked Up Damage Claim in Remitch Patent Suit
March 28, 2024
-
REGULATORY Japan’s HIV, AIDS Cases Rebound in 2023 after COVID
March 28, 2024
-
BUSINESS Sosei Group to Be Renamed “Nxera Pharma” from April
March 28, 2024
-
REGULATORY Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
March 28, 2024
-
BUSINESS Abilify Maintena Gets EU Nod as 1st 2-Month Injectable for Schizophrenia
March 28, 2024
-
BUSINESS AstraZeneca’s Japan Sales Up 8.2% in 2023 Despite Nexium Patent Cliff
March 27, 2024
-
REGULATORY Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
-
BUSINESS Incyte Appoints Eiji Ueda as Japan Chief
March 27, 2024
-
REGULATORY PMDA Chief Fujiwara to Remain Skipper for Another Term
March 27, 2024
-
BUSINESS SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
-
BUSINESS One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
-
BUSINESS Kobayashi’s Beni Koji Health Damage Reports Trigger Knock-On Recalls
March 27, 2024
-
REGULATORY PMDA to Build Shared Database of GMP Inspection Reports
March 26, 2024
-
BUSINESS CureApp Files Alcoholism Therapy App in Japan
March 26, 2024
-
REGULATORY Japan Shelves Decision on SanBio’s Lead Cell Therapy on Quality Concerns
March 26, 2024
-
ORGANIZATION Backed by 12 Pharmas, US Nonprofit’s Cloud Platform Now Up and Running to Streamline Regulatory Submissions
March 26, 2024
-
BUSINESS Eisai Settles Lenvima Patent Suit with Sun Pharma
March 26, 2024
-
BUSINESS EMA Panel Gives Go-Ahead for Xtandi Use in Earlier Setting: Astellas
March 26, 2024
-
BUSINESS Boehringer’s Brigimadlin Earns Sakigake Designation
March 26, 2024
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…